Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22790824 | 1.00 | CYP3A4 (0.32) | CYP3A4HSD17B10SPHK2SPHK1 | |
| SCHEMBL406109 | 1.00 | CYP3A4 (0.32) | CYP3A4HSD17B10SPHK2SPHK1 | |
| SCHEMBL14756148 | 1.00 | CYP3A4 (0.32) | CYP3A4HSD17B10SPHK2SPHK1 | |
| SCHEMBL20825495 | 1.00 | CYP3A4 (0.32) | CYP3A4HSD17B10SPHK2SPHK1 | |
| SCHEMBL3244476 | 0.95 | — | — | |
| SCHEMBL17914307 | 0.86 | HSD17B10 (0.39) | HSD17B10SPHK2SPHK1 | |
| SCHEMBL4373347 | 0.86 | HSD17B10 (0.39) | HSD17B10SPHK2SPHK1 | |
| SCHEMBL17914309 | 0.86 | HSD17B10 (0.39) | HSD17B10SPHK2SPHK1 | |
| SCHEMBL725089 | 0.86 | HSD17B10 (0.39) | HSD17B10SPHK2SPHK1 | |
| SCHEMBL8651797 | 0.86 | HSD17B10 (0.39) | HSD17B10SPHK2SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024112918-A1 | RNA DEGRADERS AND USES THEREOF | ARRAKIS THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-2018102725-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20120064002-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents | LEHMANN LUTZ (DE) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064002-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents | CYP4B1, CYP2B6, UGT2B7 | CYP3A4 15/4885HSD17B10 524/4885SPHK2 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.